Samsung Bioepis receives final European approval for its Remicade copy

May 30, 2016 6:15 AM

34 0

Samsung Bioepis receives final European approval for its Remicade copy

SEOUL South Korea's Samsung Bioepis said on Monday its biosimilar of Johnson & Johnson's (JNJ.N) blockbuster rheumatoid arthritis drug Remicade has received final approval from European regulators, paving the way for its second product launch in Europe.

Samsung Bioepis, an unlisted arm of South Korea's top conglomerate Samsung Group [SAGR.UL], also said last week the biosimilar had been submitted for review in the United States.

Also read: Sharp to seek all-Japan OLED alliance to counter South Korea's Samsung, LG

Read more

To category page

Loading...